Experiments have identified CD8 T cells in patients with HPV-positive head and neck cancer and identified several epitopes derived from HPV E5 protein, thus incorporating E5 as a vaccine antigen to trigger more tumor-reactive CD8 T cell responses (Eberhardt et al., 2021). Here, CD8A is linked to head and neck cancer.